Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
29 juin 2023 08h00 HE
|
Fortress Biotech, Inc.
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects Initiating Phase 1b clinical...
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
15 juin 2023 08h00 HE
|
Fortress Biotech, Inc.
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk...
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
15 mai 2023 16h01 HE
|
Fortress Biotech, Inc.
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic...
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
24 avr. 2023 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq:...
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
30 mars 2023 16h10 HE
|
Fortress Biotech, Inc.
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application...
Fortress Biotech to Participate in Two March 2023 Investor Conferences
07 mars 2023 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
16 févr. 2023 08h30 HE
|
Fortress Biotech, Inc.
Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ...
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
15 févr. 2023 08h30 HE
|
Fortress Biotech, Inc.
Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients Helocyte, Inc., a subsidiary...
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
10 févr. 2023 12h50 HE
|
Fortress Biotech, Inc.
MIAMI, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
08 févr. 2023 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...